Integrating Acridinium Ester with a Soluble Macromolecular Amplification Carrier for Ultrasensitive Detection of Aβ1-42 in Plasma

Le résumé fourni par la source

The research presents the development of a novel ultrasensitive immunoassay for the detection of amyloid-β 1-42 (Aβ1-42) in plasma, a key biomarker for Alzheimer’s disease, through the integration of a soluble signal amplification platform (Ficoll400-SA) with an acridinium ester (AE) direct chemiluminescence system. The synthesis of Ficoll400-SA was optimized to maximize the loading of AE molecules by adjusting cross-linker activation ratios and AE labeling density, achieving an approximately 35-fold enhancement of signal intensity relative to conventional streptavidin-AE conjugates. The immunoassay protocol was further refined to improve sensitivity and specificity, resulting in a limit of detection (LoD) of 0.15 pg·mL –1 and a lower limit of quantitation (LLoQ) of 0.31 pg·mL –1 . The assay exhibited excellent specificity, with negligible cross-reactivity (<0.5%) to other amyloid isoforms, high precision indicated by coefficients of variation below 8%, and robust reagent stability under both accelerated and onboard conditions. Analysis of clinical samples demonstrated strong correlation (Spearman’s ρ = 0.983) and minimal bias compared to a commercial reference method, confirming the assay’s reliability. Collectively, this study successfully expanded the application of the Ficoll400-SA signal amplification carrier from enzymatic chemiluminescence assays to the AE direct chemiluminescence platform. Moreover, these findings validate the Ficoll400-SA platform as a versatile, highly sensitive, and automatable approach for detecting low-abundance biomarkers, with significant potential to advance the early diagnosis of Alzheimer’s disease and biomarker research.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.